promiximab-mmae

Promiximab-mmae is an **antibody-drug conjugate** (ADC) designed for targeted cancer therapy, specifically for **small cell lung cancer** characterized by CD56 positivity[1]. It consists of a humanized monoclonal antibody, **promiximab**, targeting the cell surface marker **CD56** (neural cell adhesion molecule), conjugated to the **microtubule inhibitor monomethyl auristatin E (MMAE)** as the cytotoxic payload[1]. The drug’s mechanism involves binding to CD56-expressing cancer cells, internalization of the conjugate, and release of MMAE to induce cell death by disrupting microtubule dynamics. Promiximab-mmae has demonstrated potent anti-proliferative activity against CD56-positive small cell lung cancer cell lines in vitro and sustained tumor regression in xenograft mouse models without significant toxicity to major organs[1]. It is not approved for clinical use and remains an investigational agent.

Brand names

promiximab-mmae

Other names

promiximab-mmae